Kimberly Reed

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Paolo Lanzetta, Jean‐François Korobelnik, Jeffrey S. Heier et al. · The Lancet · 2024 · 179 citations

Translational Medicine, Ocular Disease, Ophthalmology +5

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy

David M. Brown, Charles C. Wykoff, David S. Boyer et al. · JAMA Ophthalmology · 2021 · 136 citations · Full text

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration

Charles C. Wykoff, David M. Brown, Kimberly Reed et al. · JAMA Ophthalmology · 2023 · 88 citations · Full text

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

David M. Brown, David S. Boyer, V. Diana et al. · The Lancet · 2024 · 78 citations

Diabetic Retinopathy, Ocular Disease, Ophthalmology +5

Fiber-Optically Controlled Pulsed Power Switches

F.J. Zutavern, Steven F. Glover, Kimberly Reed et al. · IEEE Transactions on Plasma Science · 2008 · 43 citations

Photonics, Electrical Engineering, Power Switches +15